0.01Open0.01Pre Close0 Volume1.05K Open Interest15.00Strike Price0.00Turnover490.53%IV1584.62%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0346Delta0.0732Gamma89.13Leverage Ratio-0.0018Theta0.0000Rho3.08Eff Leverage0.0002Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet